A reduced proliferation rate, as a result of OR51E2 activation, was observed in melanocytes, melanoma cells and prostate cancer cells (Neuhaus et al., 2009; Gelis et al., 2016, 2017). This evidence concerns the gene OR51E2 and prostate carcinoma.